Analysts project significant upside for the Jeuveau maker, signaling confidence in neuromodulator competition and market share gains.
Wall Street analysts covering Evolus (EOLS) are modeling 77.68% upside from current levels, according to consensus estimates. The thesis rests on Jeuveau's market penetration in the neuromodulator space and the company's ability to defend and expand share against Allergan Aesthetics' Botox and Galderma's Dysport.
Jeuveau's entry pricing and loyalty programs (Evolus Rewards) have carved out a meaningful slice of the toxin market, particularly among practices seeking rebate leverage against AbbVie's dominant position. The stock's valuation reflects near-term uncertainty around adoption rates and reimbursement headwinds, but analysts see a floor in the current price.
Analysts see 77.68% upside for Evolus stock from current levels.
For practice owners, this signals confidence in the competitive landscape. Evolus' survival and growth validate the multi-player toxin market and suggest sustained pricing discipline across the category. Practices using Jeuveau as a negotiating tool with their primary supplier should monitor analyst sentiment; significant upside could accelerate the company's ability to fund provider incentives and market development.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
